Related Experiment Video
Updated: Jun 24, 2026

A Rapid and Specific Microplate Assay for the Determination of Intra- and Extracellular Ascorbate in Cultured Cells
Published on: April 11, 2014
Gamma-glutamyltransferase-dependent resistance to arsenic trioxide in melanoma cells and cellular sensitization by
Chiara Giommarelli1, Alessandro Corti, Rosanna Supino
1Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy.
Abstract:
The cell ability of tumor cells to tolerate stress conditions is a typical feature of solid tumors. In particular, the resistance to oxidative stress of melanoma cells likely contributes to their intrinsic drug resistance. In an attempt to develop novel strategies for overcoming the mechanisms of cellular protection against oxidative stress, in this study we have explored the efficacy of the combination of two prooxidant agents in two human melanoma cell clones. The selected clones are characterized by a marked difference in expression of gamma-glutamyltransferase, which is known to produce a persistent low level of oxidative stress resulting in the stimulation of protective systems. The gamma-glutamyltransferase-overexpressing clone exhibited a low susceptibility to arsenic trioxide-induced apoptosis, associated with low reactive oxygen species induction and increased catalase activity. The combination of arsenic trioxide with subtoxic concentrations of ascorbic acid resulted in a sensitization to apoptotic cell death. The expression of protective mechanisms, in particular catalase activity, accounted for the behavior of the resistant clone. The sensitization achieved by the combination was associated with a cellular response involving the ASK1/p38 axis, which is implicated in the regulation of catalase expression and the activation of apoptotic signals. In conclusion, the results of our study provide evidence that a rational combination of prooxidant agents may be effective in overcoming cellular tolerance to oxidative stress.
Insights
Combining arsenic trioxide with ascorbic acid can overcome melanoma cell resistance to oxidative stress. This strategy targets cellular protection mechanisms, offering a novel approach to enhance cancer therapy effectiveness.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Tumor cells, particularly melanoma, exhibit resistance to oxidative stress, contributing to drug resistance.
- Melanoma cell clones with differing gamma-glutamyltransferase expression show varied responses to oxidative stress and protective system stimulation.
Purpose of the Study:
- To investigate the efficacy of combining two prooxidant agents to overcome oxidative stress tolerance in human melanoma cells.
- To explore the role of gamma-glutamyltransferase and cellular protective mechanisms in melanoma drug resistance.
Main Methods:
- Utilized two human melanoma cell clones with distinct gamma-glutamyltransferase expression levels.
- Administered arsenic trioxide and ascorbic acid in combination to assess apoptosis and reactive oxygen species induction.
- Analyzed catalase activity and the involvement of the ASK1/p38 signaling pathway.
Main Results:
- The gamma-glutamyltransferase-overexpressing clone showed resistance to arsenic trioxide-induced apoptosis, with low reactive oxygen species and high catalase activity.
- Combining arsenic trioxide with ascorbic acid sensitized resistant melanoma cells to apoptosis.
- The sensitization involved the ASK1/p38 axis, regulating catalase expression and apoptosis.
Conclusions:
- Rational combination of prooxidant agents can effectively overcome cellular tolerance to oxidative stress in melanoma.
- Targeting cellular protection mechanisms, like catalase activity via the ASK1/p38 axis, is a promising strategy for overcoming drug resistance.
Related Concept Videos
Treatment Resistant Cancers
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

